Cipro
Cipro Price range: $ 40,00 through $ 317,00
Back to products
Clarinex
Clarinex Price range: $ 51,00 through $ 196,00

Ciprodex Ophthalmic Solution

Price range: $ 63,00 through $ 95,00

Ciprodex Ophthalmic Solution is a specialized medication formulated to treat various bacterial infections of the eye. This dual-action formula combines a broad-spectrum antibiotic with a potent corticosteroid to ensure comprehensive relief. The antibiotic component works to eliminate harmful bacteria, while the steroid significantly reduces inflammation, redness, and swelling. It is primarily indicated for managing conditions like bacterial conjunctivitis and other inflammatory ocular issues. By addressing both the underlying infection and the associated symptoms, this solution promotes a faster recovery and restores ocular comfort.

Active substance: Ciprofloxacin, Dexamethasone
SKU: Ciprodex Ophthalmic Solution Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Ciprodex belongs to a class of combination topical ear preparations containing a fluoroquinolone antibacterial agent and a corticosteroid anti-inflammatory drug. It contains ciprofloxacin hydrochloride (equivalent to 0.3% ciprofloxacin base) and dexamethasone (0.1%) formulated as a sterile suspension. In the United States, this medication is available exclusively by prescription under federal law and is designated for otic administration only.

Patients prescribed this therapy receive dual-action treatment designed to target susceptible bacterial pathogens while simultaneously reducing localized inflammation and swelling. Proper administration following exact clinical guidance is necessary to achieve therapeutic efficacy and prevent potential complications.

Basic Product Summary

Active Ingredients Ciprofloxacin hydrochloride (0.3%) and Dexamethasone (0.1%)
Primary Purpose Treatment of acute otitis media with tympanostomy tubes and acute otitis externa
Route of Administration Otic (ear use only)
Prescription Status Prescription only (Rx)
Dosage Form Otic suspension
Storage Conditions Store at 20°C to 25°C (68°F to 77°F); protect from light

How the drug works

Ciprodex combines two distinct active pharmaceutical ingredients to achieve its therapeutic effect. Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic that functions by inhibiting bacterial type II topoisomerase enzymes, specifically DNA gyrase and topoisomerase IV. These enzymes are essential for bacterial DNA replication, transcription, repair, and recombination. By blocking these processes, ciprofloxacin exerts a bactericidal effect against common ear pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus.

The second active component, dexamethasone, is a synthetic corticosteroid with potent anti-inflammatory activity. It works by inhibiting the release of inflammatory mediators, decreasing vascular permeability, and suppressing cellular immune responses within the ear canal and middle ear structures. Together, this combination addresses both the underlying bacterial infection and the associated inflammation, pain, and swelling.

Main uses

The United States Food and Drug Administration (FDA) has approved this combination suspension for specific pediatric and adult otic conditions caused by susceptible isolates of designated microorganisms. The primary indication includes acute otitis media in pediatric patients (aged 6 months and older) who have tympanostomy tubes in place, typically caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, or Pseudomonas aeruginosa.

Additionally, it is FDA-approved for the treatment of acute otitis externa (commonly referred to as swimmer’s ear) in pediatric, adolescent, and adult populations (aged 6 months and older) caused by Pseudomonas aeruginosa or Staphylococcus aureus. Although ophthalmic formulations containing ciprofloxacin exist independently, Ciprodex itself is strictly formulated for otic use and must never be instilled into the eyes.

Dosing schedule

For patients with acute otitis media with tympanostomy tubes or acute otitis externa, the standard recommended dosage regimen consists of instilling 4 drops into the affected ear(s) twice daily (approximately every 12 hours) for a duration of 7 days. Before administration, the bottle should be warmed in the hand for 1 to 2 minutes to minimize dizziness that can result from instilling a cold solution into the ear canal.

The container must be shaken well immediately prior to use. Patients should lie with the affected ear facing upward during application and remain in this position for 60 seconds following instillation to ensure thorough coverage of the affected tissue. The tip of the dropper must not touch the ear, fingers, or any other surface to maintain sterility throughout the treatment course.

How it’s absorbed and eliminated

Following topical otic administration of four drops twice daily to patients with otitis media and tympanostomy tubes, systemic absorption of both ciprofloxacin and dexamethasone remains extremely low. Quantifiable plasma concentrations of ciprofloxacin are observed in a minority of patients, typically peaking within 1 to 2 hours post-instillation, with mean peak plasma levels substantially lower than those achieved following standard oral or intravenous ciprofloxacin therapy.

Similarly, dexamethasone displays minimal systemic bioavailability after topical otic application, reducing the likelihood of systemic corticosteroid adverse effects. Any small absorbed fraction of ciprofloxacin is eliminated primarily via renal excretion, while dexamethasone undergoes hepatic metabolism followed by biliary and renal clearance. The localized delivery minimizes systemic exposure while maximizing tissue concentration at the target site.

Compatibility with other medicines

Formal drug interaction studies have not been conducted with this specific topical otic suspension. Because systemic absorption following proper otic administration is minimal, clinically significant drug-drug interactions with systemic oral or intravenous medications are generally unexpected.

However, caution is advised when co-administering other topical otic preparations simultaneously. Applying multiple ear medications concurrently may dilute the active ingredients or alter the pH of the external auditory canal, potentially impairing efficacy. If additional otic treatments are prescribed, they should be administered at separate intervals as directed by a healthcare professional.

Adverse reactions

In clinical trials, this otic suspension was generally well tolerated. The most commonly reported adverse events directly attributed to the medication involve localized ear discomfort or irritation. Specific side effects occurring in a small percentage of patients include ear pruritus (itching), ear pain, ear debris accumulation, otorrhagia (ear bleeding), and temporary localized burning or stinging immediately after drop instillation.

Uncommon adverse experiences may include dysgeusia (a taste perversion, occasionally noted due to medication drainage through the Eustachian tube), headache, or localized skin rash around the pinna. Fungal or secondary bacterial superinfections may also develop during prolonged or repeated antibiotic therapy, requiring discontinuation of the drug and evaluation by a clinician.

Important precautions

This product is strictly intended for otic administration and is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, other fluoroquinolones, dexamethasone, or any excipients in the formulation. It must not be used in the eye. Treatment should be discontinued at the first sign of a skin rash or systemic allergic reaction, such as facial swelling or respiratory distress.

Prolonged use of topical antibacterial agents may promote the overgrowth of non-susceptible organisms, including fungi. If the infection does not improve after one week of continuous treatment, re-evaluation by a prescribing clinician is required. This product should not be utilized for viral infections of the external ear canal, such as herpes simplex or varicella lesions.

Signs of improvement

Patients usually begin to observe a reduction in ear pain, ear fullness, discharge, and localized swelling within 48 to 72 hours after starting treatment. Complete resolution of clinical symptoms typically occurs over the full 7-day therapeutic course. It is essential to complete the entire duration of prescribed therapy, even if symptoms subside early, to prevent microbial recurrence or the development of bacterial resistance.

If you skip a dose

If a dose is missed, it should be administered as soon as remembered, provided it is not almost time for the next scheduled application. If the next scheduled dose is due shortly, skip the missed dose and resume the regular twice-daily dosing schedule. Patients should never double the number of drops to compensate for a missed application.

Pregnancy, breastfeeding, and other groups

There are no adequate and well-controlled studies evaluating this otic suspension in pregnant women. Because systemic absorption is minimal, maternal use is expected to pose minimal risk to the fetus, though it should be used during pregnancy only if clearly needed. Ciprofloxacin and corticosteroids administered systemically pass into breast milk, but topical otic use leads to negligible serum levels; healthcare providers should weigh potential risks and benefits during lactation. Safety and effectiveness have been established in pediatric patients aged 6 months and older.

Storage and expiration

This medication should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with brief excursions permitted between 15°C and 30°C (59°F to 86°F). The container must be protected from light and kept tightly closed when not in use. Avoid freezing or exposing the bottle to excessive heat. Any remaining, unused medication should be safely discarded after the full course of treatment is finished or past the printed expiration date.

Common Questions

Can Ciprodex drops be safely used in the eyes?

No. Ciprodex is specifically formulated for otic (ear) administration only. Instilling this otic suspension into the eyes can cause severe ocular irritation, corneal damage, or chemical injury. Separate, sterile ophthalmic preparations exist for eye infections and must be prescribed specifically for ocular use.

Is it safe to use this medication if I have tympanostomy ear tubes?

Yes. FDA approval for this combination medication specifically includes pediatric patients (aged 6 months and older) who have tympanostomy tubes suffering from acute otitis media. The formulation is designed to safely treat middle ear infections through open tympanostomy tubes without causing ototoxicity.

What should I do if the drops feel uncomfortable or cold when applied?

To prevent dizziness or discomfort caused by cold liquid entering the ear, hold the bottle in your hands for 1 to 2 minutes before administration to warm the suspension to body temperature. Do not warm the bottle in hot water or a microwave, as excess heat can degrade the active ingredients.

How long should I wait before putting my ear back in contact with water or swimming?

Patients treating acute otitis externa or otitis media with tubes should avoid swimming, submerging the head in water, or allowing shower water to enter the ear canal during the entire treatment period unless explicitly authorized by their physician. Keeping the ear canal dry promotes faster healing and prevents reinfection.

This text is for informational purposes only and does not constitute individual medical advice. In accordance with FDA requirements, prescription medications should be used solely under the guidance of a licensed healthcare provider.

Additional information
Dosage

0.3%+0.1% 5ml

Package

2 flacons

,

3 flacons

,

4 flacons

,

5 flacons

Ενεργός Ουσία

,